ClinicalTrials.gg
CompletedNCT03420053Updated Apr 5, 2019

Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults

A Phase 1 interventional study of PfSPZ Vaccine and Normal Saline Placebo in Malaria and Malaria,Falciparum, sponsored by Sanaria Inc.. Completed at 1 site in Tanzania. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-05.

Primary conditionMalaria, FalciparumRegistry: MalariaReclassifiedWhy we changed it
Registry
Malaria — the first condition term the registry derived for this study.
ClinicalTrials.gg
Malaria, Falciparum
Why
  1. The study's listed conditions name Malaria, Falciparum, a narrower term within Malaria.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanaria Inc. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing PfSPZ Challenge in Malaria, Falciparum — 1 open to participants now, 1 under way, none of them phase 3. PfSPZ Challenge · Malaria, Falciparum.

Enrollment
11th of 12
21 · median 31
Started
2018
the only one that year
Phase 1
11 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
10 of 12
Sanaria Inc.

Among the 12 studies testing PfSPZ Challenge in Malaria, Falciparum, this one is the 11th largest by enrollment, is the only one that started in 2018, is one of 11 in phase 1, and was the 10th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

1 of the 12 studies testing PfSPZ Challenge in Malaria, Falciparum is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About PfSPZ Challenge

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing PfSPZ Challenge in Malaria, Falciparum, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled trial to evaluate safety and tolerability of PfSPZ Vaccine administered as five doses of 9.0x10\^5 PfSPZ or normal saline at 0, +2, +4, +6 and +28 days to healthy HIV negative adult volunteers and healthy HIV positive volunteers in Tanzania.

Read the detailed description

This trial is a single center trial designed to assess the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine (9.0x10\^5 PfSPZ given at 0, +2, +4, +6 and +28 days (Group 1, HIV negative, and Group 2, HIV positive)). Controls will receive parallel injections with normal saline (NS). All administrations of PfSPZ or NS will be by direct venous inoculation (DVI).

Twenty-one male and female adult volunteers, aged from 18 to 45 years, who live in and around the Bagamoyo township, will be enrolled based on pre-defined inclusion and exclusion criteria. 12/21 subjects will be HIV positive volunteers (who clinical stage 1) on stable anti-retroviral therapy (ART) for at least 3 months with a CD4+ cell count above 500 cells/μL at screening. The rest (9/21) will be healthy HIV negative adults.

Treatment allocation will be double-blind within Group 1 and 2b but not between the groups or subgroups. Immunizations will begin with healthy HIV negative volunteers first (Group 1), before inoculation of HIV positive volunteers (Groups 2a and 2b). Transitioning from immunization of HIV negative to immunization of HIV positive will begin by immunizing a sentinel group of 3 HIV positive individuals with a reduced vaccine dose of 4.5x10\^5 PfSPZ (Group 2a). This transition will be staggered by at least two (2) weeks, to allow for a safety data review. If the safety data do not meet pause criteria, this will signal a "go" for transitioning to immunizations of sentinel group of three (3) HIV positive volunteers. If pause criteria are met, there will be no immediate transition, and instead an ad-hoc meeting of the Safety Monitoring Committee (SMC) will be called for an independent review and recommendation. Transition from the unblinded HIV positive sentinel Group 2a to the full study cohort of double blinded placebo controlled HIV positive volunteers (Group 2b), will also be staggered for at least two (2) weeks. There will be a scheduled review by the SMC of safety data collected from the sentinel HIV positive group for up to 7 days after the fourth immunization. After the safety review, transition to the main HIV positive group (Group 2b) will take into account the SMC recommendation(s).

03

Conditions studied

  • Malaria
  • Malaria,Falciparum

Browse trials for

Keywords

  • PfSPZ Vaccine
  • HIV+
  • Plasmodium falciparum
  • Sporozoites
04

In context

Malaria, Falciparum Reclassified

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

This study's enrollment of 21 is below the median of 126 across 376 interventional studies indexed under Malaria, Falciparum.

Browse Malaria, Falciparum studies →

Lead sponsor

Sanaria Inc. is the lead sponsor of 29 studies on the registry; 4 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Compared within Malaria, Falciparum, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Malaria. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults, from 18 to 45 years of age
  • Long term (at least two years) or permanent residence in the Bagamoyo district or nearby districts in Coastal and Dar-es-Salaam regions
  • Availability through mobile phone 24 hours a day during the whole study period
  • Ability and willingness to complete the study visit schedule for safety follow-up and protocol compliance
  • Agreement to provide personal contact information and contact information of a third party household member or close friend to study team
  • Agreement not to participate in any other clinical study involving medicinal products during the study period, except enrollment in observational studies (such a co-enrollment must be approved by the PI)
  • Agreement to release medical and other information concerning for participation in the study, and to be attended by a study clinician for physical examination and clinical investigations including (ECG)
  • Willingness to undergo all blood, urine and stool tests (as specified in the protocol) and additional tests that may be ordered by the study clinician to rule-out significant abnormality(ies)
  • Female volunteers must be willing to take measures not to become pregnant if selected for participation in the trial and to undergo serum pregnancy test at screening and at defined time-points during the trial
  • Volunteers for enrollment into positive sub-groups must have:

    1. Documented HIV infection, be in general good health and on stable ART use for at least three (3) months, preferably six (6), prior to screening
    2. WHO clinical stage 1 of HIV disease
    3. >500 cells/μL at screening
    4. Attending a care and treatment centre (CTC) within the study area for medical management of HIV infection, and agreeing to maintain regular attendance to such care and treatment centre while participating in the study
    5. Agreement to allow the clinical team to contact and coordinate care with the volunteer's HIV CTC.
  • Correctly answering 10 out of 10 questions during process to demonstrate the understanding of study design, study procedures, risks and benefits
  • Signing and dating written informed consent, in accordance with local practice.

Exclusion criteria

Exclusion Criteria:

  • Previous receipt of an malaria vaccine or drug in the last 5 years
  • Receipt of standard vaccinations within 4 weeks prior to the first immunization with a PfSPZ product or are planning to take standard vaccinations during the trial through 4 weeks following the last injection with a PfSPZ product
  • Participation in any other clinical trial involving investigational medicinal products within 30 days prior to the onset of the study
  • cardiac abnormalities as indicated by history, physical examination or clinically significant abnormalities in (ECG)
  • Positive family history in a 1st or 2nd degree relative for cardiac disease at age\< 50 years old
  • A history of psychiatric disease
  • History of afebrile seizures, atypical febrile seizures or epilepsy
  • History of drug or alcohol abuse interfering with normal social function
  • History of chronic immunodeficiency condition (other than ) or disease
  • The use of chronic drugs, antibiotics, or other immune modifying drugs within three months prior to study onset (ART and inhaled and topical are allowed)
  • Meeting exclusion criteria based on the protocol algorithm for assessment of TB disease risk
  • Currently on Co-Trimoxazole (trimethoprim/sulfamethoxazole) prophylactic treatment (CPT)
  • Currently taking rifampin (isoniazid is not an exclusion criterion)
  • (BMI) of \<18 or >30 Kg/m2
  • Females who are pregnant (as indicated by positive serum pregnancy test), nursing, or plan on becoming pregnant or nurse within the duration of trial
  • Newly diagnosed with positive HIV infection at screening
  • Positive hepatitis (B or C virus) tests
  • Symptoms, physical signs and laboratory values suggestive of clinically significant systemic disorders or any other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
  • Medical, social condition or occupational reason that, in the judgment of the investigator, is a to protocol participation, may impair the volunteer's ability to give or effectively participate in the study, may significantly increase the risk to the volunteer because of participation in the study or may impair interpretation of the study data.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Group 1 HIV- vaccine recipients

    Group 1: n=6, HIV negative vaccine recipients will receive 9.0x10\^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either normal saline placebo (NS) or PfSPZ Vaccine. Efficacy will be assessed by controlled human malaria infection (CHMI) at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge

  • Placebo comparator
    Group 1 HIV- NS controls

    Group 1: n=3, HIV negative NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine. Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge.

    Other: Normal Saline Placebo · Biological: PfSPZ Challenge

  • Experimental
    Group 2a HIV+ vaccine sentinels

    Group 2a: n=3, HIV positive vaccine recipients will receive 4.5x10\^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days.

    Biological: PfSPZ Vaccine

  • Experimental
    Group 2b HIV+ vaccine recipients

    Group 2b: n=6, HIV positive vaccine recipients will receive 9.0x10\^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine. Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge

  • Placebo comparator
    Group 2b HIV+ placebo controls

    Group 2b: n=3, HIV positive NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine. Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge.

    Other: Normal Saline Placebo · Biological: PfSPZ Challenge

Interventions

  • BiologicalPfSPZ Vaccine

    Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.

  • OtherNormal Saline Placebo

    0.9% sodium chloride solution

  • BiologicalPfSPZ Challenge

    Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.

07

What researchers measure

Primary outcomes

  1. Safety of PfSPZ Vaccine - solicited symptoms

    Occurrence of solicited symptoms during a 7-day surveillance period after vaccination (day of vaccination (Vx) and +7 days post vaccination).

    Time frame: From day of vaccination to 7-days post vaccination.

  2. Safety of PfSPZ Vaccine - unsolicited symptoms

    Occurrence of unsolicited symptoms during a 28-day surveillance period after each vaccination.

    Time frame: From day of vaccination to 28-days post vaccination.

  3. Safety of PfSPZ Vaccine - laboratory abnormalities

    Occurrence of laboratory abnormalities including significant drops in CD4 T cell counts or increases in viral load.

    Time frame: Day of immunization to approximately 11 weeks after the last vaccination (approximately 36 weeks).

  4. Safety of PfSPZ Vaccine - serious adverse events

    Occurrence of serious adverse events during the study period.

    Time frame: Day of immunization to approximately 11 weeks after the last vaccination (approximately 36 weeks).

  5. Safety of PfSPZ Vaccine - breakthrough infection

    \- Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).

    Time frame: Day of immunization to approximately 11 weeks after the last vaccination (approximately 36 weeks).

08

Study locations

1 site
  • Bagamoyo Research and Training Center of the Ifakara Health Institute
    Bagamoyo, Tanzania
09

References and documents

Publications

  • Jongo S, Church LWP, Milando F, Qassim M, Schindler T, Rashid M, Tumbo A, Nyaulingo G, Bakari BM, Athuman Mbaga T, Mohamed L, Kassimu K, Simon BS, Mpina M, Zaidi I, Duffy PE, Swanson PA 2nd, Seder R, Herman JD, Mendu M, Zur Y, Alter G, Kc N, Riyahi P, Abebe Y, Murshedkar T, James ER, Billingsley PF, Sim BKL, Richie TL, Daubenberger C, Abdulla S, Hoffman SL. Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults. J Clin Invest. 2024 Jan 9;134(6):e169060. doi: 10.1172/JCI169060. PubMed 38194272 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2018, 6 months.

Of 49 phase 1 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 18. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Feb 5, 2018
StartActual
Feb 7, 2018
Primary completionActual
Aug 25, 2018
CompletionActual
Aug 25, 2018
Last update
Apr 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03420053
Lead sponsor
Sanaria Inc.
Collaborators
Ifakara Health Institute, Swiss Tropical & Public Health Institute, Medical Care Development, Inc.
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Feb 7, 2018
Primary completion
Aug 25, 2018
Completion
Aug 25, 2018
Last update
Apr 5, 2019

Study contacts

Said Jongo, MD, MMED
principal investigator · Ifakara Health Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PfSPZ Challenge

Start the discussion